During the last session, EyePoint Pharmaceuticals Inc (NASDAQ:EYPT)’s traded shares were 1.18 million, with the beta value of the company hitting 1.73. At the end of the trading day, the stock’s price was $16.47, reflecting an intraday loss of -6.26% or -$1.1. The 52-week high for the EYPT share is $30.99, that puts it down -88.16 from that peak though still a striking 65.57% gain since the share price plummeted to a 52-week low of $5.67. The company’s market capitalization is $820.70M, and the average trade volume was 989.97K shares over the past three months.
EyePoint Pharmaceuticals Inc (NASDAQ:EYPT) trade information
EyePoint Pharmaceuticals Inc (EYPT) registered a -6.26% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -6.26% in intraday trading to $16.47, hitting a weekly high. The stock’s 5-day price performance is -21.35%, and it has moved by -24.07% in 30 days. Based on these gigs, the overall price performance for the year is 112.24%.
EyePoint Pharmaceuticals Inc (EYPT) estimates and forecasts
Statistics show that EyePoint Pharmaceuticals Inc has underperformed its competitors in share price, compared to the industry in which it operates. EyePoint Pharmaceuticals Inc (EYPT) shares have gone up 143.82% during the last six months, with a year-to-date growth rate less than the industry average at 4.95% against 12.90. In the rating firms’ projections, revenue will decrease -18.30% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 9.92M as predicted by 9 analyst(s). Meanwhile, a consensus of 9 analyst(s) estimates revenue growth to 9.82M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 7.68M and 9.11M respectively. In this case, analysts expect current quarter sales to grow by 29.10% and then jump by 7.90% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 29.57%. While earnings are projected to return -3.71% in 2024.
EYPT Dividends
EyePoint Pharmaceuticals Inc is due to release its next quarterly earnings in May. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
